Department of Ophthalmology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Graduate Program in Cognitive Science, Yonsei University, Seoul, Korea.
PLoS One. 2017 Apr 19;12(4):e0175780. doi: 10.1371/journal.pone.0175780. eCollection 2017.
The aims of the study were to develop guidelines for prescribing spectacles for patients with moderate to severe hyperopic amblyopia and to demonstrate how emmetropization progresses.
Children with hyperopic amblyopia who had a spherical equivalent of ≥ +4.0 diopters (D) or more were included, while those who had astigmatism of > 2.0 D or anisometropia of > 2.0 D were excluded. The patients were divided into a full correction group and an under-correction group according to the amount of hyperopia correction applied. The under-correction group was further subdivided into a fixed under-correction group and a post-cycloplegic refraction (PCR) under-correction group. The duration of amblyopia treatment and changes in initial hyperopia were compared between the groups.
In total, 76 eyes of 38 patients were analyzed in this study. The full correction group and under-correction group were subjected to 5.5 months and 5.9 months of amblyopia treatment, respectively (P = 0.570). However, the PCR under-correction group showed more rapid improvement (2.9 months; P = 0.001). In the under-correction group, initial hyperopia was decreased by -0.28 D and -0.49 D at 6 months and 12 months, respectively, after initial cycloplegic refraction. Moreover, the amount of hyperopia under-correction was correlated with the amount of hyperopia reduction (P = 0.010).
The under-correction of moderate to severe hyperopic amblyopia has beneficial effects for treating amblyopia and activating emmetropization. PCR under-correction can more rapidly improve visual acuity, while both fixed under-correction and PCR under-correction can induce emmetropization and effectively reduce initial hyperopia.
本研究旨在制定中高度远视性弱视患者配镜的指南,并展示正视化的进展情况。
纳入远视度数≥+4.0 屈光度(D)或以上的远视性弱视儿童,排除散光>2.0 D 或屈光参差>2.0 D 的患者。根据远视矫正量将患者分为全矫组和欠矫组。根据欠矫程度将欠矫组进一步分为固定欠矫组和睫状肌麻痹后检影(PCR)欠矫组。比较各组弱视治疗持续时间和初始远视变化。
本研究共分析了 38 例患者的 76 只眼。全矫组和欠矫组分别接受了 5.5 个月和 5.9 个月的弱视治疗(P=0.570)。然而,PCR 欠矫组的改善速度更快(2.9 个月;P=0.001)。在欠矫组,初始睫状肌麻痹后 6 个月和 12 个月时,初始远视分别降低了-0.28 D 和-0.49 D。此外,欠矫量与远视降低量呈正相关(P=0.010)。
中高度远视性弱视的欠矫治疗对治疗弱视和激活正视化有有益作用。PCR 欠矫可更快速地提高视力,而固定欠矫和 PCR 欠矫均可诱导正视化并有效降低初始远视。